At present, several bioengineered molecules harnessing the NKG2D pathway against cancer have been developed such as antibodies that block MIC protein shedding, the extracellular NKG2D domain fused to immune activating components, and the NKG2D-based chimeric antigen receptor (CAR.NKG2D) [reviewed in Ref (69).]. This evidence concerns the gene KLRK1 and cancer.